OXERVATE® is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis (NK).

Prescribing Information

CONNECT to Care

 

Dompé CONNECT to Care

Access support and more through a single point of contact

Providing practices and patients with assistance every step of the way

Program enrollment

Benefits verification

Prior authorizations

Patient financial assistance

Delivery coordination
& confirmation

General questions

Since approval in 2018, more than 2000 total ophthalmologists and optometrists have prescribed OXERVATE®1

Patient Enrollment

How to enroll a patient

Submit a Patient Enrollment Form

A completed enrollment form serves as the OXERVATE® prescription and enrolls the patient into Dompé CONNECT to Care.
1

Fax completed enrollment form
on the patient’s behalf.

DOWNLOAD FORM
OR
2

Use the iAssist digital portal
to complete enrollment.

GO TO iASSIST

Remember: Patient Authorization section of enrollment form must be completed.

Questions? Contact Dompé CONNECT to Care

Phone 1-877-422-4412
Fax 1-855-263-1775

With Dompé copay support, a majority of patients with commercial insurance who were prescribed OXERVATE paid no more than $100 out-of-pocket for an 8-week course of therapy2

Sign up for additional resources and to stay up to date about OXERVATE®

For US healthcare professionals only.

Important Safety Information

WARNINGS AND PRECAUTIONS

Contact lenses, either therapeutic or corrective, should be removed before applying OXERVATE. Contact lenses may be reinserted 15 minutes after OXERVATE administration.

Eye Discomfort, such as eye pain, that can be mild to moderate can occur with OXERVATE. Patients should contact their health care provider if a more serious eye reaction occurs.

ADVERSE REACTIONS

The most common adverse reaction with OXERVATE (~16%) was eye pain. Other adverse reactions with OXERVATE (1% to 10%) included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.

Please read the full Prescribing Information for OXERVATE.

References: 1. Data on File. Dompé Hub Data (REF-01027). Dompé U.S. Inc.; 2025. 2. Data on File. Pharmacy Adjudicated Claims Report (REF-01024). Dompé U.S. Inc.; 2025.